Lilly, Aduro Biotech in Immunotherapy Alliance

Eli Lilly and Co. and Aduro Biotech, Inc. have entered a research collaboration and exclusive license agreement for Aduro's cGAS-STING Pathway Inhibitor program for the development of novel immunotherapies for autoimmune and other inflammatory diseases.